These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1813207)

  • 21. [Epithelial cancer of the ovary: current data].
    Ozols RF
    Bull Cancer; 1993 Nov; 80(11):955-70. PubMed ID: 7915918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
    Chen DX; Li FQ
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology of the ovary.
    McGowan L
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):580-6. PubMed ID: 1878514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX; Schwartz PE; Li FQ
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA-125 monitoring in the management of ovarian cancer.
    Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
    Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor markers for the diagnosis, prognosis, treatment and follow-up of gynaecological tumors.
    Ulsperger E; Karrer K
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):33-43. PubMed ID: 2545372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
    Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New technology of diagnosis of ovarian cancer].
    Terashima Y
    Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigens associated with epithelial ovarian carcinomas.
    Bast RC
    Prog Clin Biol Res; 1989; 288():73-83. PubMed ID: 2785696
    [No Abstract]   [Full Text] [Related]  

  • 33. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
    Sagan DL; Chebotareva ED; Evtushenko GV
    Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
    Silver HK; Archibald BL; Ragaz J; Coldman AJ
    Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical significance of CA 130 assay as a tumor marker].
    Ariyoshi Y; Kuwabara M
    Nihon Rinsho; 1990 Feb; 48 Suppl():985-8. PubMed ID: 2355640
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.